皇家华人

Imagine if you had to hand-sew one piece of garden hose to another to connect them. Now imagine you have a few to do, and if you don鈥檛 do them quickly and correctly, your lawn could die. Oh, and make the hoses 1.5 to 4mm in diameter.

It may sound ridiculous, but this the sort of thing surgeons do in reconstructive surgery. For example, breast reconstruction surgery involves bringing in tissue from another part of the patient鈥檚 body and connecting the veins and arteries so bloodflow 鈥� and therefore tissue life 鈥� can be maintained. These types of surgeries can take as long as 16 hours.

As a plastic surgery resident, Dr Nandoun Abeysekera took part in many microvascular surgeries. There was a coupler to connect veins 鈥� a device comparable to the ring you use on garden hoses. However, there was nothing for arteries.

Veins are the blood vessels that take oxygen-poor blood back to the heart. They鈥檙e thin and stretchy. Arteries bring oxygen-rich blood from the heart to the rest of the body. They have a thicker and stiffer muscular wall to withstand the pressure of the heart鈥檚 pumping.

If surgeons were to use vein couplers on arteries, they would risk introducing vascular injuries such as tearing the vessel鈥檚 wall. This could result in thrombosis 鈥� clots blocking blood vessels 鈥� or leaks. A clot could result in the death of the transplanted tissue.

Abeysekera was always interested in engineering 鈥� it was what his father did. A rocket lover as a young child, his interests shifted to civil engineering when he was older as he helped his dad with renovation projects around the family鈥檚 Auckland home.

Then, in his teens, he became interested in bioengineering 鈥� inspired by none other than the cartoon show Batman of the Future.

鈥淏atman in that universe had the coolest suit,鈥� says Abeysekera. 鈥淚t augmented all human functioning through tech, which got me interested in what you could do with the human body.鈥�

A bright teen, Abeysekera went to the University of Auckland at 17 and pursued an accelerated pathway that allowed him to complete a Bachelor of Biomedical Engineering at age 19. After that, interested in medicine for its opportunities to connect with people and alleviate suffering, he entered med school.

鈥淭he Velocity programme really changed the way I understood this project and helped define some of the goals and directions of the company. The material I produced, like the business proposal, is still relevant today, five years later,鈥� he says.

Today, Avasa is based in Cloud 9, ABI鈥檚 ninth-floor incubator space. The company raised funds through a 2022 seed round led by Bridgewest and now employs two engineers in addition to Abeysekera, who left surgery in 2018 to pursue his start-up, though he still works part time as a general practitioner to keep an oar in the clinical space.

It took Abeysekera years of iterations to come up with a design he was confident about.

His arterial coupler relies on eversion 鈥� exposing the inner lining of the vessel 鈥� to facilitate connection with another artery.

Pins lock each side in place, so the artery connection procedure only takes five minutes. Made of biocompatible materials, Abeysekera believes the device will be proven safe to leave in the body as vein couplers are.

In 2021, Abeysekera successfully carried out a live animal study in which his arterial coupler was used to reconnect a pig鈥檚 3mm femoral artery and re-establish blood flow.

鈥淭hat was amazing. It was a surreal moment seeing years of work realised in a live study that very closely mirrored what you鈥檇 encounter in human reconstructive microsurgery,鈥� says Abeysekera.

Avasa has started conversations with the U.S. Food and Drug Administration (FDA) and has established a fast regulatory pathway for clearance in the States. Abeysekera expects to have enough data for an FDA submission around the second quarter of 2024.

There鈥檚 still a lot of testing ahead before the device can be certified 鈥� more animal studies, biocompatibility testing, sterilisation validation 鈥� as well manufacturing details to work out. If all goes to plan, Avasa鈥檚 device should enter the U.S. market by the first or second quarter of 2025.

It鈥檚 a long road 鈥� longer than Abeysekera expected 鈥� but the same vision that led to the project still drives him.

鈥淧atients will have safer surgeries,鈥� he says. 鈥淭hey鈥檒l experience fewer complications. Surgeons will be able to perform reconstructive microsurgery safely and efficiently, so they鈥檒l be able to do more. Different types of surgeons will be able to do these surgeries as well because of the simplification of the process.鈥�

In future, Abeysekera says he expects the scope of his device to expand to other surgical fields such as organ transplants, cardiothoracic surgery and vascular surgery.

鈥淚 want to keep innovating and solving problems to improve health outcomes for people.鈥�